Ser444
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser444  -  HOMEZ (human)

Site Information
tPPPSTRsLNERAEt   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 23113816

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
gastric cancer ( 3 ) , gastric carcinoma ( 3 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 )
Relevant cell line - cell type - tissue:
Calu 6 (pulmonary) ( 2 ) , H2077 (pulmonary) ( 2 ) , H322M (pulmonary) ( 2 ) , HCC2279 (pulmonary) ( 2 ) , K562 (erythroid) ( 1 ) , MKN-45 (gastric) ( 3 ) , NCI-H157 (pulmonary) ( 2 ) , NCI-H1648 (pulmonary) ( 2 ) , NCI-H1666 (pulmonary) ( 2 ) , NCI-H2172 (pulmonary) ( 2 )

References 

1

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

2

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

3

Mulhern D (2011) CST Curation Set: 12863; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.